CoChat
Sign Up
Cited by 135Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis

Open access
Mahan, Thomas E., Wang, Chao, Bao, Xin, Choudhury, Ankit, Ulrich, Jason D., Holtzman, David M.·2022·Molecular Neurodegeneration
DOI 10.1186/s13024-022-00516-0PMC PMC8811969
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: One of the key pathological hallmarks of Alzheimer disease (AD) is the accumulation of the amyloid-β (Aβ) peptide into amyloid plaques. The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset AD and has been shown to influence the accumulation of Aβ in the brain in an isoform-dependent manner. ApoE can be produced by different cell types in the brain, with astrocytes being the largest producer of apoE, although reactive microglia also express high levels of apoE. While studies have shown that altering apoE levels in the brain can influence the development of Aβ plaque pathology, it is not fully known how apoE produced by specific cell types, such as astrocytes, contributes to amyloid pathology. Methods: We utilized APOE knock-in mice capable of having APOE selectively removed from astrocytes in a tamoxifen-inducible manner and crossed them with the APP/PS1-21 mouse model of amyloidosis. We analyzed the changes to Aβ plaque levels and assessed the impact on cellular responses to Aβ plaques when astrocytic APOE is removed. Results: Tamoxifen administration was capable of strongly reducing apoE levels in the brain by markedly reducing astrocyte apoE, while microglial apoE expression remained. Reduction of astrocytic apoE3 and apoE4 led to a large decrease in Aβ plaque deposition and less compact plaques. While overall Iba1+ microglia were unchanged in the cortex after reducing astrocyte apoE, the expression of the disease-associated microglial markers Clec7a and apoE were lower around amyloid plaques, indicating decreased microglial activation. Additionally, astrocyte GFAP levels are unchanged around amyloid plaques, but overall GFAP levels are reduced in the cortex of female apoE4 mice after a reduction in astrocytic apoE. Finally, while the amount of neuritic dystrophy around remaining individual plaques was increased with the removal of astrocytic apoE, the overall amount of cortical amyloid-associated neuritic dystrophy was significantly decreased. Conclusion: This study reveals an important role of astrocytic apoE3 and apoE4 on the deposition and accumulation of Aβ plaques as well as on certain Aβ-associated downstream effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-022-00516-0

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tamoxifen administration reduces ApoE levels in Aldh1l1-Cre + APPPS1;FE3Cre- and APPPS1;FE4Cre- mice. A Timeline of the experimental scheme. Mice were given once-daily IP injections of tamoxifen (TAM) (100 mg TAM/kg body weight) at 4 weeks of age for 6 consecutive days. Sample collection and analysis occurred at 18 weeks of age. B APOE mRNA expression levels in Cre- and Cre + FE3, FE4, APPPS1;FE3, and APPPS1;FE4 mice. Cortical tissue samples were analyzed by qPCR (n = 9). C Soluble apoE levels in the cortex of Cre- or Cre + mice. Cortical tissue samples were homogenized in PBS and PBS-soluble apoE protein levels were analyzed by ELISA (n = 9–19). D Insoluble apoE levels in the cortex of Cre- or Cre + mice. PBS-insoluble cortex tissue samples from (C) were further homogenized in 5 M guanidine HCl to determine the amount of PBS-insoluble apoE that was guanidine-soluble. Protein levels were analyzed by ELISA (n = 9–19). E ApoE immunostaining in the cortex and hippocampus of Cre-and Cre + mice. Representative images are of female brain sections stained with an anti-apoE antibody. Scale bars = 300 μm. F Intensity of fluorescent apoE staining in Cre- or Cre + mice. The average pixel intensity was analyzed from images of apoE immunostained brain sections (n = 10–19). G Brain sections from female APPPS1;FE4Cre- and APPPS1;FE4Cre + mice co-stained for X-34 (blue), apoE (green), GFAP (red), and Iba1 (magenta). White arrows indicate co-localization of apoE with GFAP and green arrows indicate co-localization of apoE with Iba1. Scale bars = 50 μm. A-G * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001; two-way ANOVA and Sidak’s post hoc test in (B), three-way ANOVA and Sidak’s post hoc test in (D); three-way ANOVA and uncorrected Fisher’s LSD test in (C) and (F). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 1 Tamoxifen administration reduces ApoE levels in Aldh1l1-Cre + APPPS1;FE3Cre- and APPPS1;FE4Cre- mice. A Timeline of the experimental scheme. Mice were given once-daily IP injections of tamoxifen (TAM) (100 mg TAM/kg body weight) at 4 weeks of age for 6 consecutive days. Sample collection and analysis occurred at 18 weeks of age. B APOE mRNA expression levels in Cre- and Cre + FE3, FE4, APPPS1;FE3, and APPPS1;FE4 mice. Cortical tissue samples were analyzed by qPCR (n = 9). C Soluble apoE levels in the cortex of Cre- or Cre + mice. Cortical tissue samples were homogenized in PBS and PBS-soluble apoE protein levels were analyzed by ELISA (n = 9–19). D Insoluble apoE levels in the cortex of Cre- or Cre + mice. PBS-insoluble cortex tissue samples from (C) were further homogenized in 5 M guanidine HCl to determine the amount of PBS-insoluble apoE that was guanidine-soluble. Protein levels were analyzed by ELISA (n = 9–19). E ApoE immunostaining in the cortex and hippocampus of Cre-and Cre + mice. Representative images are of female brain sections stained with an anti-apoE antibody. Scale bars = 300 μm. F Intensity of fluorescent apoE staining in Cre- or Cre + mice. The average pixel intensity was analyzed from images of apoE immunostained brain sections (n = 10–19). G Brain sections from female APPPS1;FE4Cre- and APPPS1;FE4Cre + mice co-stained for X-34 (blue), apoE (green), GFAP (red), and Iba1 (magenta). White arrows indicate co-localization of apoE with GFAP and green arrows indicate co-localization of apoE with Iba1. Scale bars = 50 μm. A-G * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001; two-way ANOVA and Sidak’s post hoc test in (B), three-way ANOVA and Sidak’s post hoc test in (D); three-way ANOVA and uncorrected Fisher’s LSD test in (C) and (F). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central
Fig. 2 Reducing astrocytic apoE decreases fibrillar plaque levels and plaque intensity. A Fibrillar amyloid plaque staining in the cortex and hippocampus of female Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34 (blue) stained female brain sections. Scale bars = 1000 μm (B) Fibrillar plaque load in the cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by fibrillar plaque was determined by analyzing X-34 stained brain sections (n = 10–18). C Fibrillar plaque load in hippocampus of Cre-, Cre+, and APPPS1EKO mice. Percent of hippocampus area covered by fibrillar plaque was determined by analyzing X-34 stained brain sections (n = 10–18). D Intensity of fibrillar amyloid plaques in Cre-, Cre+, and APPPS1EKO mice. Representative images are of female X-34 stained amyloid plaques. Scale bars = 20 μm. E Measure of average pixel intensity of X-34 stained fibrillar plaques in the cortex of Cre-, Cre+, and APPPS1EKO mice (n = 9–16). A-E * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (C), and (E). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 2 Reducing astrocytic apoE decreases fibrillar plaque levels and plaque intensity. A Fibrillar amyloid plaque staining in the cortex and hippocampus of female Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34 (blue) stained female brain sections. Scale bars = 1000 μm (B) Fibrillar plaque load in the cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by fibrillar plaque was determined by analyzing X-34 stained brain sections (n = 10–18). C Fibrillar plaque load in hippocampus of Cre-, Cre+, and APPPS1EKO mice. Percent of hippocampus area covered by fibrillar plaque was determined by analyzing X-34 stained brain sections (n = 10–18). D Intensity of fibrillar amyloid plaques in Cre-, Cre+, and APPPS1EKO mice. Representative images are of female X-34 stained amyloid plaques. Scale bars = 20 μm. E Measure of average pixel intensity of X-34 stained fibrillar plaques in the cortex of Cre-, Cre+, and APPPS1EKO mice (n = 9–16). A-E * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (C), and (E). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central
Fig. 3 Reducing astrocytic apoE decreases Aβ plaque levels and alters Aβ deposition. A Aβ plaque staining in the cortex and hippocampus of Cre-, Cre+, and APPPS1EKO mice. Representative images are of Aβ immunostained female brain sections using the HJ3.4 anti-Aβ antibody (orange). Scale bars = 1000 μm. B Aβ plaque load in cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by Aβ plaque was determined by analyzing HJ3.4 stained brain sections (n = 10–18). C Aβ plaque load in the hippocampus of Cre-, Cre+, and APPPS1EKO mice. Percent of hippocampus area covered by Aβ plaque was determined by analyzing HJ3.4 stained brain sections (n = 10–18). D Insoluble Aβ40 levels in the cortex of Cre- and Cre + mice. PBS-insoluble cortical tissue samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA to determine the guanidine-soluble Aβ40 levels (n = 9–19). E Insoluble Aβ42 levels in the cortex of Cre- and Cre + mice. PBS-insoluble cortex tissue samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA to determine the guanidine-soluble Aβ42 levels (n = 9–19). F Deposition pattern of Aβ plaque and fibrillar amyloid plaque staining in Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34 (blue) and HJ3.4 (orange) co-stained male brain sections. Scale bars = 50 μm. G Ratio of fibrillar Aβ plaques to total Aβ deposition in Cre-, Cre+, and APPPS1EKO. The ratio was determined by dividing the area of X-34 staining by the area of HJ3.4 staining. (n = 6–16) (A-F) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B) and (C); three-way ANOVA and uncorrected Fisher’s LSD test in (D), (E), and (G). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 3 Reducing astrocytic apoE decreases Aβ plaque levels and alters Aβ deposition. A Aβ plaque staining in the cortex and hippocampus of Cre-, Cre+, and APPPS1EKO mice. Representative images are of Aβ immunostained female brain sections using the HJ3.4 anti-Aβ antibody (orange). Scale bars = 1000 μm. B Aβ plaque load in cortex of Cre-, Cre+, and APPPS1EKO mice. Percent of cortex area covered by Aβ plaque was determined by analyzing HJ3.4 stained brain sections (n = 10–18). C Aβ plaque load in the hippocampus of Cre-, Cre+, and APPPS1EKO mice. Percent of hippocampus area covered by Aβ plaque was determined by analyzing HJ3.4 stained brain sections (n = 10–18). D Insoluble Aβ40 levels in the cortex of Cre- and Cre + mice. PBS-insoluble cortical tissue samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA to determine the guanidine-soluble Aβ40 levels (n = 9–19). E Insoluble Aβ42 levels in the cortex of Cre- and Cre + mice. PBS-insoluble cortex tissue samples that were further homogenized in 5 M guanidine HCl were analyzed by ELISA to determine the guanidine-soluble Aβ42 levels (n = 9–19). F Deposition pattern of Aβ plaque and fibrillar amyloid plaque staining in Cre-, Cre+, and APPPS1EKO mice. Representative images are of X-34 (blue) and HJ3.4 (orange) co-stained male brain sections. Scale bars = 50 μm. G Ratio of fibrillar Aβ plaques to total Aβ deposition in Cre-, Cre+, and APPPS1EKO. The ratio was determined by dividing the area of X-34 staining by the area of HJ3.4 staining. (n = 6–16) (A-F) * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B) and (C); three-way ANOVA and uncorrected Fisher’s LSD test in (D), (E), and (G). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central
Fig. 4 Microglial activation is reduced in mice with a decrease in astrocytic apoE. A Microglia staining in the cortex and hippocampus of female Cre- and Cre + mice. Representative images are of female brain sections immunostained using an anti-Iba1 antibody (red). Scale bars = 200 μm. B Microglial coverage in the cortex of Cre- and Cre + mice. Percent of cortex area covered by microglia was determined by analyzing Iba1 stained brain sections (n = 10–19). C ApoE+ microglia around fibrillar amyloid plaques in female Cre- and Cre + mice. Representative images are of apoE immunostaining (green) using an anti-apoE antibody and microglia immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained (blue) amyloid plaques. ApoE co-localized with Iba1 appears white. Scale bars = 20 μm. D Microglial apoE levels around fibrillar amyloid plaques in Cre- and Cre + mice. Area of apoE+ microglia per total microglia area was determined by analyzing the level of apoE+ microglia staining to total microglia staining within 10 μm of X-34 stained plaques (n = 5–12). E Microglia clustering and activated microglia around fibrillar amyloid plaques in female Cre- and Cre + mice. Representative images are of Clec7a immunostaining (green), using an anti-Clec7a antibody, and microglia immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained (blue) amyloid plaques. Clec7a co-localized with Iba1 appears white. Scale bars = 20 μm. F Clustering of microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area covered by microglia around fibrillar amyloid plaques was determined by analyzing the level of Iba1 staining within 15 μm of X-34 stained plaques (n = 6–14). G Coverage of activated microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area of activated microglia around fibrillar amyloid plaques was determined by analyzing the level of cleca7a staining within 15 μm of X-34 stained plaques per total area of Iba1 (n = 6–14). A-G * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (D), (F), and (G). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 4 Microglial activation is reduced in mice with a decrease in astrocytic apoE. A Microglia staining in the cortex and hippocampus of female Cre- and Cre + mice. Representative images are of female brain sections immunostained using an anti-Iba1 antibody (red). Scale bars = 200 μm. B Microglial coverage in the cortex of Cre- and Cre + mice. Percent of cortex area covered by microglia was determined by analyzing Iba1 stained brain sections (n = 10–19). C ApoE+ microglia around fibrillar amyloid plaques in female Cre- and Cre + mice. Representative images are of apoE immunostaining (green) using an anti-apoE antibody and microglia immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained (blue) amyloid plaques. ApoE co-localized with Iba1 appears white. Scale bars = 20 μm. D Microglial apoE levels around fibrillar amyloid plaques in Cre- and Cre + mice. Area of apoE+ microglia per total microglia area was determined by analyzing the level of apoE+ microglia staining to total microglia staining within 10 μm of X-34 stained plaques (n = 5–12). E Microglia clustering and activated microglia around fibrillar amyloid plaques in female Cre- and Cre + mice. Representative images are of Clec7a immunostaining (green), using an anti-Clec7a antibody, and microglia immunostaining using an anti-Iba1 antibody (magenta) around X-34 stained (blue) amyloid plaques. Clec7a co-localized with Iba1 appears white. Scale bars = 20 μm. F Clustering of microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area covered by microglia around fibrillar amyloid plaques was determined by analyzing the level of Iba1 staining within 15 μm of X-34 stained plaques (n = 6–14). G Coverage of activated microglia around fibrillar amyloid plaques in Cre- or Cre + mice. Area of activated microglia around fibrillar amyloid plaques was determined by analyzing the level of cleca7a staining within 15 μm of X-34 stained plaques per total area of Iba1 (n = 6–14). A-G * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001; three-way ANOVA and uncorrected Fisher’s LSD test in (B), (D), (F), and (G). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central
Fig. 5 Astrocyte activation is reduced in APPPS1;FE4Cre + mice. A Gene expression analysis of S100β in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of S100β gene levels assessed by qPCR from cortical tissue samples (n = 3–9). B Gene expression analysis of GFAP in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of GFAP gene levels assessed by qPCR from cortical tissue samples (n = 3–9). C Activated astrocyte staining in female Cre- and Cre + mice. Representative images in the top panel are of the cortex and hippocampus from brain sections immunostained using an anti-GFAP antibody (green). Images in the bottom panels are of GFAP immunostaining (green), using an anti-GFAP antibody, around X-34 stained amyloid plaques (blue). Scale bars = 200 μm (top panels), 20um (bottom panels). D Astrocyte activation in the cortex of Cre- or Cre + mice. Percent of cortical area covered by activated astrocytes was determined by analyzing GFAP stained brain sections (n = 10–14). E Astrocyte activation around fibrillar amyloid plaques in Cre- and Cre + mice. The volume of activated astrocyte processes around fibrillar amyloid plaques was determined by analyzing the amount of GFAP staining within 15 μm of X-34 stained plaques. GFAP volume was divided by the X-34 volume to normalize to the amount of plaque and account for differences in plaque size (n = 8–19). A-D * p ≤ 0.05, ** p ≤ 0.01; three way ANOVA and uncorrected Fisher’s LSD test in (A), (B), (D), and (E). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 5 Astrocyte activation is reduced in APPPS1;FE4Cre + mice. A Gene expression analysis of S100β in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of S100β gene levels assessed by qPCR from cortical tissue samples (n = 3–9). B Gene expression analysis of GFAP in Cre-, Cre + FE3Cre-, FE3Cre+, FE4Cre-, and FE4Cre + mice. Graph is of GFAP gene levels assessed by qPCR from cortical tissue samples (n = 3–9). C Activated astrocyte staining in female Cre- and Cre + mice. Representative images in the top panel are of the cortex and hippocampus from brain sections immunostained using an anti-GFAP antibody (green). Images in the bottom panels are of GFAP immunostaining (green), using an anti-GFAP antibody, around X-34 stained amyloid plaques (blue). Scale bars = 200 μm (top panels), 20um (bottom panels). D Astrocyte activation in the cortex of Cre- or Cre + mice. Percent of cortical area covered by activated astrocytes was determined by analyzing GFAP stained brain sections (n = 10–14). E Astrocyte activation around fibrillar amyloid plaques in Cre- and Cre + mice. The volume of activated astrocyte processes around fibrillar amyloid plaques was determined by analyzing the amount of GFAP staining within 15 μm of X-34 stained plaques. GFAP volume was divided by the X-34 volume to normalize to the amount of plaque and account for differences in plaque size (n = 8–19). A-D * p ≤ 0.05, ** p ≤ 0.01; three way ANOVA and uncorrected Fisher’s LSD test in (A), (B), (D), and (E). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central
Fig. 6 Neuritic dystrophy is increased around plaques, but decreased overall, with a reduction in astrocytic apoE. A Dystrophic neurite staining in the cortex and hippocampus of Cre- and Cre + mice. Representative images are of brain sections immunostained using an anti-BACE1 antibody (red). Scale bars = 1000 μm. B Level of neuritic dystrophy in the cortex of Cre- and Cre + mice. Percent of cortical area covered by dystrophic neurites was determined by analyzing BACE1 stained brain sections (n = 10–19). C Dystrophic neurites around fibrillar amyloid plaques in Cre- and Cre + mice (BACE1). Representative images are of BACE1 immunostaining (red), using an anti-BACE1 antibody, around X-34 stained (blue) amyloid plaques. Scale bars = 20 μm. D Level of neuritic dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (BACE1). Percent of area covered by dystrophic neurites around fibrillar amyloid plaques was determined by analyzing the level of BACE1 staining within 15 μm of X-34 stained plaques (n = 6–18). E Dystrophic neurites around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Representative images are of female RTN-3 immunostaining (red), using an anti-RTN-3 antibody, around X-34 stained (blue) amyloid plaques. Scale bars = 20 μm. F Level of neuritic dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Percent of area covered by dystrophic neurites around fibrillar amyloid plaques was determined by analyzing the level of RTN-3 staining within 15 μm of X-34 stained plaques (n = 6–14). A-D * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B); three-way ANOVA and uncorrected Fisher’s LSD test in (D) and (F). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statistics
Fig. 6 Neuritic dystrophy is increased around plaques, but decreased overall, with a reduction in astrocytic apoE. A Dystrophic neurite staining in the cortex and hippocampus of Cre- and Cre + mice. Representative images are of brain sections immunostained using an anti-BACE1 antibody (red). Scale bars = 1000 μm. B Level of neuritic dystrophy in the cortex of Cre- and Cre + mice. Percent of cortical area covered by dystrophic neurites was determined by analyzing BACE1 stained brain sections (n = 10–19). C Dystrophic neurites around fibrillar amyloid plaques in Cre- and Cre + mice (BACE1). Representative images are of BACE1 immunostaining (red), using an anti-BACE1 antibody, around X-34 stained (blue) amyloid plaques. Scale bars = 20 μm. D Level of neuritic dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (BACE1). Percent of area covered by dystrophic neurites around fibrillar amyloid plaques was determined by analyzing the level of BACE1 staining within 15 μm of X-34 stained plaques (n = 6–18). E Dystrophic neurites around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Representative images are of female RTN-3 immunostaining (red), using an anti-RTN-3 antibody, around X-34 stained (blue) amyloid plaques. Scale bars = 20 μm. F Level of neuritic dystrophy around fibrillar amyloid plaques in Cre- and Cre + mice (RTN-3). Percent of area covered by dystrophic neurites around fibrillar amyloid plaques was determined by analyzing the level of RTN-3 staining within 15 μm of X-34 stained plaques (n = 6–14). A-D * p ≤ 0.05, ** p ≤ 0.01, and **** p ≤ 0.0001; three-way ANOVA and Sidak’s post hoc test in (B); three-way ANOVA and uncorrected Fisher’s LSD test in (D) and (F). Data are expressed as mean ± SEM. See Supplementary Table 1 for detailed statisticsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Research works printed but not linked: 1

  1. International AD, Guerchet M, Prince M. Numbers of people with dementia around the world. 2020.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M.
Affiliations
Washington University in St. Louis (US)
Corresponding author
Holtzman, David M.
ORCID
Venue
Molecular Neurodegeneration
Publisher
Springer Science and Business Media LLC
Published
2022-02-02
Volume
17
Issue
1
Pages
13-13
ISSN
1750-1326 (ISSN-L)
DOI
10.1186/s13024-022-00516-0
PMC
PMC8811969
OpenAlex
W4210382695
Cited by
134
References
87
Citations by year
2026: 19 · 2025: 35 · 2024: 31 · 2023: 29 · 2022: 20
FWCI
17.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • cure alzheimer's fund
  • jpb foundation
  • national institute of neurological disorders and stroke (NS090932)
  • national institute on aging (AG047644)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
apolipoprotein E, astrocytes, APOE3, APOE ε4, amyloid-beta, amyloid plaques, Alzheimer's disease, APP/PS1 mice, microglial activation, Dectin-1, glial fibrillary acidic protein, neuritic dystrophy
MeSH terms
Alzheimer Disease, Amyloidosis, Animals, Astrocytes, Female, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Apolipoprotein E3, Apolipoprotein E4, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review